Kinaset Therapeutics raises $103 million in an oversubscribed Series B led by RA Capital Management and Forge Life Science Partners to advance its inhaled asthma treatment.
Amount Raised
$103 Million
Round Type
Series B
MedfieldHealthcareHealth CareInvestors
Description
Kinaset Therapeutics has closed a $103 million Series B financing round to further develop frevecitinib, an inhaled therapy for severe asthma. Led by RA Capital Management and Forge Life Science Partners, this financing includes participation from various new and existing investors. The funds will support a Phase 2 clinical study for the treatment of severe inflammatory respiratory disease. This milestone is pivotal for Kinaset Therapeutics in executing its vision.
Quick answer
Kinaset Therapeutics raised $103 Million in a Series B round, dated January 10, 2026. Investors: Vivo Capital, EQT Life Sciences, 5AM Ventures, Gimv, Schroders Capital, Willett Advisors, Pictet Alternative Advisors and Sixty Degree Capital. Kinaset Therapeutics is based in Medfield, Massachusetts, United States.
- How much did Kinaset Therapeutics raise?
- Kinaset Therapeutics raised $103 Million in a Series B round on January 10, 2026.
- Who invested in Kinaset Therapeutics?
- Vivo Capital, EQT Life Sciences, 5AM Ventures, Gimv, Schroders Capital, Willett Advisors, Pictet Alternative Advisors and Sixty Degree Capital are named as investors in this round.
- What does Kinaset Therapeutics do?
- Kinaset Therapeutics is a clinical-stage biotechnology company focused on developing novel respiratory therapies for patients with intractable diseases, combining an experienced team with a potentially best-in-class..
- Where is Kinaset Therapeutics based and how big is it?
- Kinaset Therapeutics is based in Medfield, Massachusetts, United States.
- Who are the decision-makers at Kinaset Therapeutics?
- Fundz holds 1 contact at Kinaset Therapeutics, including the Executive Officer, Director, Promoter. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Healthcare and Health Care around the same time
Companies in the same sectors as Kinaset Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- Handl Health raised $14M (Series A) on February 24, 2026.
- Korsana Biosciences raised $175M (Series A) on February 18, 2026.
- Levee Medical raised $12M (Funding Round) on February 17, 2026.
- Aatru Medical raised $150K on February 10, 2026.
- KoKo Medical raised $8M on February 6, 2026.
- Dentologie Enterprises raised $5.6M on February 5, 2026.
Who to call at Kinaset Therapeutics, and when
A new round usually means Kinaset Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Kinaset Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Kinaset Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Kinaset Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Kinaset Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansKinaset Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.